• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Rep. Cummings talks drug pricing with HHS chief

January 16, 2019 By Sarah Faulkner

Prescription drugsDays after unveiling an investigation into the drug pricing practices of 12 pharmaceutical companies, House Oversight Committee Chairman Rep. Elijah Cummings (D-Md.) met with the Secretary of Health & Human Services, Alex Azar, to discuss ways they can work together to lower drug prices.

Although the two did not discuss specific legislation, Cummings told reporters he was encouraged by the meeting and felt that they could reach a bipartisan consensus on the matter.

“We share the same goal so that was good enough for me,” Cummings said, according to The Hill.

“Secretary Azar and the Trump Administration appreciate Chairman Cummings’s leadership in calling attention to the issue of skyrocketing drug costs,” Azar spokeswoman Caitlin Oakley told the news outlet.

“The Administration is committed to working with Democrats and Republicans to accomplish what was set forth in the President’s blueprint on drug prices, to make sure Americans see lower prices and reduced out-of-pocket costs,” Oakley added.

Democrats and President Donald Trump have made lowering drug prices a priority, although they have not always agreed on how to achieve that goal.

Last week, Cummings and fellow Democrats introduced legislation that aims to rein in drug prices. The legislation includes proposals such as allowing Medicare to negotiate drug prices. Trump has previously supported that idea, but his administration does not currently endorse it.

As part of Cummings’ investigation into drug prices, the committee chairman asked 12 pharmaceutical companies to submit information relating to R&D practices, corporate strategies and any communications related to price hikes.

Drug-delivery devices, such as Novo Nordisk’s Novolog Flexpen for people with diabetes and AbbVie’s Humira pen for people with arthritis, made the list of products that Cummings plans to investigate.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Pharmaceuticals

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS